RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response
durations remain elusive as a result of the inherent ability of prostate cancer cells to
develop iterative resistance. The goal of this study is to learn if the study drug RAD001
together with Bicalutamide can slow the growth of prostate cancer. The safety of the
combination will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Novartis Pharmaceuticals